ArticleCyborg and bionic systems (Washington, D.C.)2021
3D Bioprinted Spheroidal Droplets for Engineering the Heterocellular Coupling between Cardiomyocytes and Cardiac Fibroblasts.
Article in Cyborg and bionic systems (Washington, D.C.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- 3D Bioprinting Functional Engineered Heart Tissues.International journal of molecular sciences · 2025Review
- Generation and applications of cardiac spheroids.npj biomedical innovations · 2025Review
- Cardiac Tissue Engineering for Translational Cardiology: From In Vitro Models to Regenerative Therapies.Bioengineering (Basel, Switzerland) · 2025Review
- Bioprinting approaches in cardiac tissue engineering to reproduce blood-pumping heart function.iScience · 2025Review
- Spheroids from Epithelial and Mesenchymal Cell Phenotypes as Building Blocks in Bioprinting (Review).Sovremennye tekhnologii v meditsine · 2025Review
- Advances in the Model Structure of In Vitro Vascularized Organ-on-a-Chip.Cyborg and bionic systems (Washington, D.C.) · 2024Article
- Assembly of ceria-Nrf2 nanoparticles as macrophage-targeting ROS scavengers protects against myocardial infarction.Frontiers in pharmacology · 2024Article
- A Semi-Three-Dimensional Bioprinted Neurocardiac System for Tissue Engineering of a Cardiac Autonomic Nervous System Model.Bioengineering (Basel, Switzerland) · 2023Article
- Lightweight Structural Biomaterials with Excellent Mechanical Performance: A Review.Biomimetics (Basel, Switzerland) · 2023Review
- Inhibition of ERK 1/2 pathway downregulates YAP1/TAZ signaling in human cardiomyocytes exposed to hyperglycemic conditions.Biochemical and biophysical research communications · 2023Article
- Demonstration of doxorubicin's cardiotoxicity and screening using a 3D bioprinted spheroidal droplet-based system.RSC advances · 2023Article
- Engineering In vitro Models: Bioprinting of Organoids with Artificial Intelligence.Cyborg and bionic systems (Washington, D.C.) · 2023Article
- Advances in the design, generation, and application of tissue-engineered myocardial equivalents.Frontiers in bioengineering and biotechnology · 2023Review
- Engineering approaches for cardiac organoid formation and their characterization.Translational research : the journal of laboratory and clinical medicine · 2022Review
- 3D Biofabrication of a Cardiac Tissue Construct for Sustained Longevity and Function.ACS applied materials & interfaces · 2022Article
- Development and Characterization of Furfuryl-Gelatin Electrospun Scaffolds for Cardiac Tissue Engineering.ACS omega · 2022Article
- Hydrogel-Based Stimuli-Responsive Micromotors for Biomedicine.Cyborg and bionic systems (Washington, D.C.) · 2022Review
- Biohybrid Micro- and Nanorobots for Intelligent Drug Delivery.Cyborg and bionic systems (Washington, D.C.) · 2022Review
- A Manta Ray-Inspired Biosyncretic Robot with Stable Controllability by Dynamic Electric Stimulation.Cyborg and bionic systems (Washington, D.C.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Since conventional human cardiac two-dimensional (2D) cell culture and multilayered three-dimensional (3D) models fail in recapitulating cellular complexity and possess inferior translational capacity, we designed and developed a high-throughput scalable 3D bioprinted cardiac spheroidal droplet-organoid model with cardiomyocytes and cardiac fibroblasts that can be used for drug screening or regenerative engineering applications. This study helped establish the parameters for bioprinting and cross-linking a gelatin-alginate-based bioink into 3D spheroidal droplets. A flattened disk-like structure developed in prior studies from our laboratory was used as a control. The microstructural and mechanical stability of the 3D spheroidal droplets was assessed and was found to be ideal for a cardiac scaffold. Adult human cardiac fibroblasts and AC16 cardiomyocytes were mixed in the bioink and bioprinted. Live-dead assay and flow cytometry analysis revealed robust biocompatibility of the 3D spheroidal droplets that supported the growth and proliferation of the cardiac cells in the long-term cultures. Moreover, the heterocellular gap junctional coupling between the cardiomyocytes and cardiac fibroblasts further validated the 3D cardiac spheroidal droplet model.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.